Dr. Kathy Giacomini is a Professor in the Department of Bioengineering and Therapeutic Sciences. She was chair of the department of Bioengineering and Therapeutic Sciences between 2000 and 2014. In the late 2000s, she chaired the NIH Pharmacogenomics Research Network (PGRN), and is now Co-Principal Investigator of the NIH PGRN Hub. She is also the Co-Principal Investigator of the UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation (CERSI), a major center funded by the FDA with the goal of advancing scientific research and education related to the safe and effective use of medical products. She received her Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo and completed a post-doctoral fellowship at Stanford University. Dr. Giacomini is considered a leader in the field of membrane transporters. She and her group discovered and functionally characterized over 100 transporter polymorphisms, identifying both gain of function and loss of function variants that may lead to variation in drug response. In large genomewide association studies she and her team discovered genetic variants in transporters associated with response to the anti-diabetic drug, metformin and the anti-gout medication, allopurinol. Kathy has been recognized by many awards: she is a recipient of an honorary doctoral degree from Uppsala University and an elected member of the National Academy of Medicine.